I-Telix Pharmaceuticals Limited namuhla imemezele ukuthi isiguli sokuqala sinikezwe umthamo ocwaningweni lwe-'STARLITE 2' Phase II lweNkampani yokwelapha umdlavuza wezinso, i-TLX250 (177Lu-DOTA-girentuximab), e-Memorial Sloan Kettering Cancer Center (MSK) eNew York. .
I-STARLITE 2 (NCT05239533) izohlola ukusebenza kahle kwemisebe ehlosiwe ye-TLX250 ihlanganiswe ne-immunotherapy ye-clean cell renal cell carcinoma (ccRCC), uhlobo oluvame kakhulu nolunolaka lomdlavuza wezinso. I-TLX250 iqondise i-carbonic anhydrase IX (CA9),[1] iphrotheni evezwa kakhulu ezigulini okungenzeka zibonise ukusabela okulinganiselwe ku-immunotherapy yomdlavuza.[2] Umqondo uwukuthi imithamo ephansi yemisebe eqondiwe inganqoba ukumelana nokuzivikela komzimba - noma "i-immune prime" isimila futhi ngenxa yalokho isenze siphendule kakhudlwana ku-cancer immunotherapy.
Lolu cwaningo lweSigaba sesi-II, ezigulini eziqhubekele phambili ngokulandela ukwelashwa kwamasosha omzimba ngaphambilini, zizohlola imisebe ekhiqizwe i-TLX250 ngokuhlangana ne-anti-PD-1[3] immunotherapy Opdivo®[4] (nivolumab). Isiphetho esiyinhloko siwukunquma ukuphepha nokusebenza ngempumelelo kokwelashwa okuhlangene ne-TLX250 njengoba kuhlolwa izimila ezisabela ekwelashweni kwe-Telix ngokumelene nezinga lamanje lokunakekela kuphela. I-ejenti yophenyo engumngane ka-Telix i-TLX250-CDx (89Zr-DFO-girentuximab) izophinda isetshenziswe ocwaningweni ukuze kufanekiswe isisho se-CA9. Ucwaningo oluholwa umphenyi wengalo eyodwa kulindeleke ukuthi lubhalise cishe iziguli ezingama-30.
Isikhulu Sezokwelapha Sakwa-Telix, uDkt. Colin Hayward saphawula, “Ukuhlanganiswa kwemithi yenuzi enembayo kanye ne-oncology yezokwelapha kuyaqhubeka futhi u-Telix uhamba phambili kulo mnyakazo ukuze athuthukise imikhiqizo yomuntu siqu kanye nemithi elungele isiguli. Sifisa ukuzwakalisa ukubonga kwethu kuDkt. Darren Feldman nethimba lakhe lomtholampilo, kanye neziguli ezizobamba iqhaza kulolu cwaningo oluyisiqalo.”
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- The primary endpoint is to determine the safety and efficacy of combination therapy with TLX250 as assessed by the tumours responding to the Telix therapy versus the current standard of care alone.
- TLX250 targets carbonic anhydrase IX (CA9),[1] a protein that is highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy.
- STARLITE 2 (NCT05239533) will assess the efficacy of TLX250 targeted radiation in combination with immunotherapy for clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.
